AstraZeneca's Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
February 24 2017 - 10:26AM
Dow Jones News
By Olga Cotaga
LONDON--AstraZeneca PLC (AZN.LN) Friday said it has received
approval from a key committee of the European Medicines Agency for
a new drug treatment for hyperkalaemia.
Approval of ZS-9 from the Committee for Medicinal Products for
Human Use moves the drug a step closer towards formal approval from
the European Commission. The commission usually agrees with the
committee's suggestions.
Hyperkalaemia is a condition characterized by high potassium
levels in the blood serum caused by cardiovascular, renal and
metabolic diseases.
At 1245 GMT AstraZeneca's shares were down 22 pence, or 0.5%, at
4578.5 pence valuing the company at 57.9 billion pounds ($72.3
billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
February 24, 2017 10:11 ET (15:11 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
